Omar Abdel-Rahman
Abdel-Rahman, Omar M.
VIAF ID: 201016763 (Personal)
Permalink: http://viaf.org/viaf/201016763
Preferred Forms
- 100 1 _ ‡a Abdel-Rahman, Omar M.
- 100 0 _ ‡a Omar Abdel-Rahman
4xx's: Alternate Name Forms (6)
5xx's: Related Names (1)
Works
Title | Sources |
---|---|
Impact of tumor size on the outcome of patients with small renal cell carcinoma | |
Incorporating age into International Germ Cell Consensus Classification (IGCCC): a time to move forward? | |
Insulin-like growth factor pathway aberrations and gastric cancer; evaluation of prognostic significance and assessment of therapeutic potentials. | |
Irinotecan-based regimens for recurrent glioblastoma multiforme: [corrected] a systematic review. | |
Is routine baseline brain imaging needed for all newly diagnosed non-small-cell lung cancer patients? | |
Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic analysis for the Global Burden of Disease Study 2017 | |
MET Inhibitors for the Treatment of Gastric Cancer: What's Their Potential? | |
Modified staging system for pulmonary carcinoids on the basis of lung cancer TNM system. | |
Outcomes of clinically localized prostate cancer patients managed with initial monitoring approach versus upfront local treatment: a North American population-based study | |
Outcomes of non-metastatic poorly differentiated gastroenteropancreatic neuroendocrine neoplasms treated with surgery: a real-world population-based study | |
Patterns of on-treatment cardiac adverse events within three clinical trials of adjuvant anthracycline-based chemotherapy | |
Predictors of skeletal-related events among cancer patients with bone metastases treated with zoledronic acid: a secondary analysis of a randomized study | |
Predictors of toxicity-related hospitalization in four randomized studies of 5-fluorouracil-based chemotherapy in metastatic colorectal cancer | |
Principles of a risk evaluation and mitigation strategy (REMS) for breast cancer patients receiving potentially cardiotoxic adjuvant treatments | |
Prognostic Value of Baseline ALBI Score Among Patients With Colorectal Liver Metastases: A Pooled Analysis of Two Randomized Trials | |
Prognostic value of HPV status among patients with hypopharyngeal carcinoma: a population-based study | |
Prostascore: A Simplified Tool for Predicting Outcomes among Patients with Treatment-naive Advanced Prostate Cancer. | |
Prostate Cancer Incidence and Mortality in Relationship to Family History of Prostate Cancer; Findings From The PLCO Trial | |
RAF signaling in neuroendocrine neoplasms: from bench to bedside. | |
Real-world patterns of chemotherapy administration and attrition among patients with metastatic colorectal cancer | |
Revisiting Dukes' paradigm; some node positive colon cancer patients have better prognosis than some node negative patients. | |
Revisiting the Prognostic Heterogeneity of AJCC Stage IV Carcinomas of the Upper Urinary Tract | |
Risk of cardiac death among cancer survivors in the United States: a SEER database analysis. | |
Risk of elevated transaminases in non-small cell lung cancer (NSCLC) patients treated with erlotinib, gefitinib and afatinib: a meta-analysis. | |
Risk of mucocutaneous toxicities in patients with solid tumors treated with sunitinib: a critical review and meta analysis. | |
Risk of selected gastrointestinal toxicities in breast cancer patients treated with regimens containing lapatinib; a pooled analysis of randomized controlled studies | |
Risk of Subsequent Primary Kidney Cancer After Another Malignancy: A Population-based Study. | |
Rolapitant: a pooled analysis of its efficacy and safety in the prophylaxis of chemotherapy-induced nausea and vomiting. | |
S-1-based regimens and the risk of oral and gastrointestinal mucosal injury: a meta-analysis with comparison to other fluoropyrimidines | |
S-1-based regimens for locally advanced/metastatic non-small-cell lung cancer: a meta-analysis | |
Smoking and EGFR status may predict outcomes of advanced NSCLC treated with PD-(L)1 inhibitors beyond first line: A meta-analysis. | |
Somatostatin receptor expression in hepatocellular carcinoma: prognostic and therapeutic considerations. | |
Sorafenib for Egyptian patients with advanced hepatocellular carcinoma; single center experience | |
Sorafenib plus tegafur-uracil (UFT) versus sorafenib as first line systemic treatment for patients with advanced stage HCC: a Phase II trial (ESLC01 study) | |
Sphenoidal esthesioneuroblastoma treated with sequential chemo radiotherapy: a case report and review of the literature. | |
Squamous Cell Carcinoma of the Bladder: A SEER Database Analysis. | |
Statin treatment and outcomes of metastatic pancreatic cancer: a pooled analysis of two phase III studies | |
Subtype-specific risk factors for postmenopausal breast cancer: findings from the PLCO trial | |
Systemic therapy for hepatocellular carcinoma (HCC): from bench to bedside | |
Systemic therapy options for malignant pleural mesothelioma beyond first-line therapy: a systematic review. | |
Targeting FGF receptors in colorectal cancer: from bench side to bed side | |
Targeting platelet-derived growth factor (PDGF) signaling in gastrointestinal cancers: preclinical and clinical considerations | |
Targeting the hepatocyte growth factor/mesenchymal epithelial transition pathway in gastric cancer: biological rationale and clinical applications. | |
Targeting vascular endothelial growth factor (VEGF) pathway in iodine-refractory differentiated thyroid carcinoma (DTC): from bench to bedside | |
Temozolomide-based combination for advanced neuroendocrine neoplasms: a systematic review of the literature. | |
Treatment at a high-volume centre is associated with improved survival among patients with non-metastatic hepatocellular carcinoma. | |
Treatment choices and outcomes of non-metastatic hepatocellular carcinoma patients in relationship to neighborhood socioeconomic status: a population-based study | |
Treatment-related Death in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. | |
Trends in pancreatic adenocarcinoma incidence and mortality in the United States in the last four decades; a SEER-based study. | |
Use of angiotensin-converting enzyme inhibitors in the prophylaxis of anthracycline or trastuzumab-related cardiac dysfunction: preclinical and clinical considerations | |
Validation of the 8th AJCC staging system for gastric cancer in a population-based setting. | |
Validation of the Eighth AJCC New Substages for Bladder Cancer Among Different Staging Contexts. | |
Validation of the prognostic value of new sub-stages within the AJCC 8th edition of non-small cell lung cancer | |
Vascular endothelial growth factor (VEGF) pathway and neuroendocrine neoplasms (NENs): prognostic and therapeutic considerations. | |
Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma |